Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 2/3 1

Status

Terminated 1Recruiting 1Completed 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Dermatologic 34CNS 5Thoracic 3Gastrointestinal 3Head & Neck 2Gynecologic 2Plasma cell 1Other hematologic neoplasm 1Myeloid 1Endocrine 1

Conditions

Colorectal Neoplasms 8Pancreatic Neoplasms 5Carcinoma, Non-Small-Cell Lung 5Ovarian Neoplasms 4Neoplasms 4Melanoma 3Gastrointestinal Neoplasms 3Cholangiocarcinoma 3Breast Neoplasms 3Urinary Bladder Neoplasms 2Prostatic Neoplasms 2Neoplasms by Site 2Multiple Myeloma 2Hematologic Neoplasms 2Gallbladder Neoplasms 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Thyroid Neoplasms 1Thyroid Carcinoma, Anaplastic 1Thyroid Cancer, Papillary 1Thrombocytosis 1Thoracic Neoplasms 1Skin Neoplasms 1Sarcoma 1Respiratory Tract Neoplasms 1Respiratory Tract Diseases 1Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pancreatic Adenocarcinoma 1Noonan Syndrome 1

Interventions

pembrolizumab 59Nivolumab 34Cyclophosphamide 21fludarabine 15Paclitaxel 12Ipilimumab 12atezolizumab 11Specimen Handling 11Magnetic Resonance Spectroscopy 10Carboplatin 10Docetaxel 9Cisplatin 9Gemcitabine 8Biopsy 8durvalumab 7aldesleukin 7Radiosurgery 7Interleukin-2 7Bevacizumab 7cemiplimab 6Pemetrexed 6fludarabine phosphate 5avelumab 5Radiotherapy 5Drug Therapy 5spartalizumab 4epacadostat 4enzalutamide 4Taxes 4Sirolimus 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Melanoma × cobimetinib × Gastrointestinal × Clear all
NCT05768178 2025-11-24

DETERMINE

Cancer Research UK

Phase 2/3 Recruiting
30 enrolled
CNSDermatologicEndocrineGastrointestinalGynecologicHead & NeckMyeloidOther hematologic neoplasmPlasma cellThoracic

Thyroid Cancer, Papillary, Carcinoma, Non-Small-Cell Lung, Glioma, Laryngeal Neoplasms, Melanoma, Multiple Myeloma, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Ovarian Neoplasms, Colorectal Neoplasms, Hematologic Neoplasms, Erdheim-Chester Disease, Thyroid Carcinoma, Anaplastic

NCT04190628 2024-05-21

Safety and Tolerability of ABM-1310 in Patients With Advanced Solid Tumors

ABM Therapeutics Corporation

Phase 1 Terminated
53 enrolled
CNSDermatologicGastrointestinalGynecologicHead & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Glioblastoma, Melanoma, Ovarian Neoplasms, Thyroid Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma

NCT02457793 2018-11-20

A Study of the Safety, Tolerability, and Effects of Cobimetinib and GDC-0994 in Patients With Locally Advanced or Metastatic Solid Tumors

Genentech, Inc.

Phase 1 Completed
24 enrolled 27 charts
DermatologicGastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Melanoma, Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡